Julieta Iglesia Rothberg

Director Of Accounting And Financial Reporting at PureTech Health

Julieta Iglesia Rothberg, CPA, has a diverse range of work experiences in accounting and financial reporting. Julieta Iglesia is currently serving as the Director of Accounting and Financial Reporting at PureTech Health, a position they started in June 2021. Before joining PureTech Health, they worked as an Assistant Controller at Mi9 Retail from February 2019 to April 2020. Prior to that, they served as the SEC Financial Reporting Assistant Manager at Amerant Bank from July 2018 to December 2018. Julieta also worked as a Senior Accountant at World Fuel Services from July 2016 to June 2018, and as a Controller at BattleFrog OCR Series from January 2016 to July 2016. Julieta Iglesia has also held positions as a Senior Fund Accountant at Parmenter from August 2012 to January 2014, a Senior Financial Analyst at GenSpring - SunTrust Private Wealth from June 2010 to January 2011, and as a Senior Auditor at Deloitte & Touche from September 2000 to September 2003. Additionally, Julieta has entrepreneurial experience, having served as a CFO/Entrepreneur/Partner in the real estate portfolio at Industry Holdings from September 2003 to December 2010.

Julieta Iglesia Rothberg, CPA has a strong educational background in accounting and finance. Julieta Iglesia obtained a Bachelor's degree in Accounting from the Florida International University - College of Business in 1998. Julieta Iglesia then pursued further education at the same institution and completed a Master's degree in Accounting in 2000. Later, in 2009, they expanded their knowledge by earning a Master's degree in Finance from the Florida International University - College of Business.

Location

Miami Beach, United States

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


PureTech Health

4 followers

PureTech (Nasdaq: PRTC, LSE: PRTC) is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others.


Industries

Employees

51-200

Links